Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Source Confirms Hong Kong Main Port Of Mainland China Counterfeit Drugs

This article was originally published in PharmAsia News

Executive Summary

Hong Kong remains at the center of the flow of counterfeit drugs from mainland China to other countries, according to a pharmacy industry source in the city. The source said illicit activities are able to move more easily through Hong Kong than other places because it is a free port. Counterfeit drugs on foreign markets, primarily from the Chinese mainland, include those for treating cholesterol, diabetes and heart and liver problems. The Office of the U.S. Trade Representative issued a report last year naming Hong Kong, the Philippines, Thailand, Paraguay and Ukraine as having "significant problems" with smuggled counterfeits. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067621

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel